Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NVNO 
enVVeno Medical Corp (NVNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/22/2025: NVNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.43% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.27M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 0.94 | 52 Weeks Range 0.67 - 5.62 | Updated Date 10/22/2025 |
52 Weeks Range 0.67 - 5.62 | Updated Date 10/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.59% | Return on Equity (TTM) -64.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -15946346 | Price to Sales(TTM) - |
Enterprise Value -15946346 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.87 | Shares Outstanding 19247141 | Shares Floating 16446297 |
Shares Outstanding 19247141 | Shares Floating 16446297 | ||
Percent Insiders 0.81 | Percent Institutions 30.13 |
Upturn AI SWOT
enVVeno Medical Corp
Company Overview
History and Background
enVVeno Medical Corp is a medical device company focused on the development of innovative solutions for the treatment of chronic venous disease. Founded in 2018, the company is still in its early stages, with a focus on clinical trials and regulatory approvals.
Core Business Areas
- Venous Disease Treatment: Development of BioVac, a minimally invasive surgical device designed for percutaneous transluminal angioplasty of the lower extremity deep veins in patients with chronic venous disease.
Leadership and Structure
The company has a leadership team focused on medical device development and commercialization. The exact organizational structure is not publicly detailed.
Top Products and Market Share
Key Offerings
- BioVac: BioVac is enVVeno Medical Corp's primary product, a minimally invasive surgical device for percutaneous transluminal angioplasty of the lower extremity deep veins in patients with chronic venous disease. Market share data is not yet available as the product is pending FDA approval. Competitors include companies offering angioplasty balloons and stents, such as Medtronic (MDT), Boston Scientific (BSX), and Cook Medical.
Market Dynamics
Industry Overview
The venous disease treatment market is growing due to an aging population and increasing prevalence of chronic venous insufficiency. The market is competitive, with established players and emerging companies.
Positioning
enVVeno Medical Corp aims to differentiate itself through its BioVac technology, offering a potentially less invasive and more effective treatment option for venous disease.
Total Addressable Market (TAM)
The global market for venous disease treatment is estimated to be in the billions of dollars. enVVeno Medical Corp is positioned to capture a share of this market with successful commercialization of BioVac.
Upturn SWOT Analysis
Strengths
- Innovative technology (BioVac)
- Focus on unmet need in venous disease treatment
- Potential for less invasive treatment
Weaknesses
- Reliance on single product (BioVac)
- Limited financial resources
- Lack of commercialization experience
Opportunities
- FDA approval for BioVac
- Expansion into new markets
- Partnerships with established medical device companies
Threats
- Competition from established players
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MDT
- BSX
Competitive Landscape
enVVeno Medical Corp faces strong competition from established medical device companies with larger resources and existing market presence. Its success depends on the efficacy and adoption of its BioVac technology.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to early stage.
Future Projections: Future growth depends on successful FDA approval and commercialization of BioVac. Analyst estimates are not readily available.
Recent Initiatives: Focus is on completing clinical trials and seeking regulatory approval for BioVac.
Summary
enVVeno Medical Corp is a high-risk, high-reward company in the early stages of development. Its future depends on successful FDA approval and commercialization of its BioVac technology. The company faces significant competition from established players and needs to manage its limited resources effectively. Approval of BioVac would be a major catalyst.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Press releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment in enVVeno Medical Corp carries significant risks. Market share data is estimated based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enVVeno Medical Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2018-05-31 | CEO & Director Mr. Robert A. Berman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://www.envveno.com |
Full time employees 37 | Website https://www.envveno.com | ||
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.